MedTrace Logo

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

NCT02689921 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-09-28

No results posted yet for this study

Summary

This is a prospective, single-arm, phase II study of 32 evaluable patients treated with NEOADjuvant Aromatase inhibitor and Pertuzumab/Trastuzumab (NEOADAPT) without chemotherapy for hormone receptor positive (HR+), \[i.e. Estrogen Receptor positive (ER+) and/or Progesterone Receptor positive (PR+)\] HER2+ localized, non-metastatic stage I - IIb breast cancer.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Exemestane

Aromatase inhibitor

DRUG

Letrozole

Aromatase inhibitor

DRUG

Anastrozole

Aromatase inhibitor

DRUG

Leuprolide Acetate

Luteinizing Hormone-Releasing Hormone agonist

DRUG

Pertuzumab

Monoclonal antibody (HER2/neu receptor antagonist)

DRUG

Trastuzumab

Monoclonal antibody (HER2/neu receptor antagonist)

Sponsors & Collaborators

  • Midwestern Regional Medical Center

    lead OTHER

Principal Investigators

  • Eugene Ahn, MD · Midwestern Regional Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02689921 on ClinicalTrials.gov